Navigation Links
New Study Published in Lancet Respiratory Medicine Highlights QIAGEN's QuantiFERON-TB Potential to Predict Active Tuberculosis Risk in Infants
Date:2/16/2017

HILDEN, Germany and GERMANTOWN, Maryland, February 16, 2017 /PRNewswire/ --

Results Suggest Benefits of Quantitative Screening of Young Children in Countries With High TB Burden 

QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced that data published in The Lancet Respiratory Medicine journal shows screening with QuantiFERON-TB Gold (QFT) can detect latent tuberculosis (TB) infection in otherwise healthy young children and can predict which are likely to progress to the active stage of this life-threatening respiratory disease.

Continue Reading
QuantiFERON-TB blood test (PRNewsFoto/QIAGEN N.V.)
QuantiFERON-TB blood test (PRNewsFoto/QIAGEN N.V.)

(Photo: http://mma.prnewswire.com/media/468908/QuantiFERON_TB_Blood_Test.jpg )

Results from the study of more than 2,500 young children in South Africa suggest that screening with the modern QuantiFERON-TB blood test could save lives in countries with a high TB burden by identifying those children most at risk of developing active disease. The study noted young children are particularly vulnerable to TB, with up to 20% of those infected by the bacteria developing the active TB disease.

"This study marks a true milestone. For the first time, there is a test that has demonstrated the potential to quantify the risk for young children to develop active tuberculosis. Researchers found that those with a QuantiFERON-TB test result above a certain threshold were far more likely than others to get sick with the active disease. TB is a terrible killer of children in high-burden countries, so early diagnosis and treatment could save many lives," said Dr. Masae Kawamura, Senior Director, TB Medical and Scientific Affairs, at QIAGEN.

Click here for full press release:

https://www.qiagen.com/about-us/press-releases/pressreleaseview?ID={049783C5-174E-41FE-974D-1662A6DBD416}&lang=en

Contacts: QIAGEN Investor Relations John Gilardi +49-2103-29-11711 e-mail: ir@QIAGEN.com Public Relations Dr. Thomas Theuringer +49-2103-29-11826 e-mail: pr@QIAGEN.com


'/>"/>
SOURCE QIAGEN N.V.
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Advocacy Study Highlights Top Locations for High-Growth Companies
2. Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis
3. New Study Shows Full Spectrum Endoscopy Procedure Reduces The Miss Rate of Adenomas During Colonoscopy
4. Study Shows Whole-Cell Vaccine was More Effective than Acellular Vaccine During California Pertussis Outbreak
5. AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy
6. Rhythm Announces Study Demonstrating High Prevalence of Diabetic Gastroparesis Symptoms in the U.S.
7. Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain
8. Ceregene Reports Additional Efficacy Data From Parkinsons Disease Phase 2b Study
9. Primary Efficacy and Safety Findings from Phase 3 Study of Janssens Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients
10. Grifols study demonstrates higher dose of PROLASTIN-C increases levels of alpha1-PI to within normal range in patients with AAT deficiency
11. Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... , Oct. 11, 2017  True Health, ... has amplified its effort during National Breast Cancer ... hereditary cancer risks. ... Clinical Oncology calculated that more than 10 million ... inherited mutations in BRCA1 or BRCA2 and have not ...
(Date:10/5/2017)... , Oct. 5, 2017  In response to ... Oral and Maxillofacial Surgeons (AAOMS) released prescribing recommendations ... to be used as a first-line therapy to ... Recognizing the value ... White Paper "Opioid Prescribing: Acute and Postoperative Pain ...
(Date:10/2/2017)... 2017  Eli Lilly and Company (NYSE: ... third quarter of 2017 on Tuesday, October 24, 2017. ... day with the investment community and media to further ... call will begin at 9 a.m. Eastern time. Investors, ... webcast of the conference call through a link that ...
Breaking Medicine Technology:
(Date:10/13/2017)... LUIS OBISPO, Calif. (PRWEB) , ... October 13, 2017 , ... ... Alzheimer’s or dementia. However, many long-term care insurance companies have a waiver for care ... is the 90-day elimination period, when the family pays for care, is often waived, ...
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House ... most popular and least understood books in the Holy Scriptures, Revelation. The Book of ... baffled scholars for centuries. Many have tossed it off as mere rubbish, but Yisrayl ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the ... “America On The Brink” is the creation of published author, William Nowers. Captain ... As a WWII veteran, he spent thirty years in the Navy. Following his ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has developed a ... and regulatory authorities worldwide. From Children’s to Adults 50+, every formula has been ... standard. , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the ... to develop to enable prevention of a major side effect of chemotherapy in ... in pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a ...
Breaking Medicine News(10 mins):